Human CD19-CD22 Targeted T Cells not checked

Hrain Biotechnology Co., Ltd. · CD19-CD22 CAR-T

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.”In the company’s words, NCT05223686 on ClinicalTrials.gov
Tested for
Acute Lymphoblastic Leukemia
Main trialPhase 1
“To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19-CD22 CAR+ T cells.”In the company’s words, NCT05223686 on ClinicalTrials.gov
Other names
CD19-CD22 CAR-T

Other drugs for Acute Lymphoblastic Leukemia

All 58 drugs for Acute Lymphoblastic Leukemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown 10 Jun 2023 To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Human CD19-CD22 Targeted T Cells

Following is part of Solo: you see every change to Human CD19-CD22 Targeted T Cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in